Anandamide, but not 2‐arachidonoylglycerol, accumulates during in vivo neurodegeneration
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Endogenous cannabinoid receptor ligands (endocannabinoids) may rescue neurons from glutamate excitotoxicity. As these substances also accumulate in cultured immature neurons following neuronal damage, elevated endocannabinoid concentrations may be interpreted as a putative neuroprotective response. However, it is not known how glutamatergic insults affect in vivo endocannabinoid homeostasis, i.e. N‐arachidonoylethanolamine (anandamide) and 2‐arachidonoylglycerol (2‐AG), as well as other constituents of their lipid families, N‐acylethanolamines (NAEs) and 2‐monoacylglycerols (2‐MAGs), respectively. Here we employed three in vivo neonatal rat models characterized by widespread neurodegeneration as a consequence of altered glutamatergic neurotransmission and assessed changes in endocannabinoid homeostasis. A 46‐fold increase of cortical NAE concentrations (anandamide, 13‐fold) was noted 24 h after intracerebral NMDA injection, while less severe insults triggered by mild concussive head trauma or NMDA receptor blockade produced a less pronounced NAE accumulation. By contrast, levels of 2‐AG and other 2‐MAGs were virtually unaffected by the insults employed, rendering it likely that key enzymes in biosynthetic pathways of the two different endocannabinoid structures are not equally associated to intracellular events that cause neuronal damage in vivo. Analysis of cannabinoid CB 1 receptor mRNA expression and binding capacity revealed that cortical subfields exhibited an up‐regulation of these parameters following mild concussive head trauma and exposure to NMDA receptor blockade. This may suggest that mild to moderate brain injury may trigger elevated endocannabinoid activity via concomitant increase of anandamide levels, but not 2‐AG, and CB 1 receptor density.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913 · cited 2×
“N-arachidonoylethanolamine (anandamide) and 2-arachidonoylglycerol (2-AG) (Devane et al. 1992; Mechoulam et al. 1995; Sugiura et al. 1995), has fuelled interest in how this novel receptor-ligand system relates to brain function.”
Background2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Blockade of NMDA Receptors and Apoptotic Neurodegeneration in the Developing Brain
Ikonomidou, C., Bosch, F., Miksa, M., Bittigau, P., Vöckler, J., Dikranian, K., Tenkova, T. I., Stefovska, V., Turski, L., & Olney, J. W. (1999) · Science · doi:10.1126/science.283.5398.70 · Cited by 2,055
Self-citationThe Role of Excitotoxicity in Neurodegenerative Disease
Doble, A. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00042-4 · Cited by 723 · cited 2×
“In the context of excitotoxic phenomena, glutamatergic pathological processes are usually reinforced by simultaneous calcium ion over ̄ow in affected brain regions (Doble 1999), suggesting that in vivo pathological brain processes with an excitotoxic component provide very powerful stimulatory signals for NAE formatio…”
BackgroundThe endocannabinoid system as a target for therapeutic drugs
Piomelli, D., Giuffrida, A., Calignano, A., & Rodrı́guez de Fonseca, F. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01482-6 · Cited by 421
Ikonomidou, C., Mosinger, J., Salles, K., Labruyere, J., & Olney, J. (1989) · The Journal of Neuroscience · doi:10.1523/jneurosci.09-08-02809.1989 · Cited by 332 · cited 3×
“…of the NMDA subtype of glutamate receptors triggers excitotoxic neurodegeneration whereas blockade of NMDA receptors results in widespread neuronal loss (Ikonomidou et al. 1989, 1999; q 2001 International Society for Neurochemistry, Journal of Neurochemistry, 78, 1415±1427 Pohl et al. 1999).”
BackgroundMethodResultSelf-citation
Cited by
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
“Finally, brain levels of endocannabinoids are increased during ischemic (Schmid et al., 1995; Schabitz et al., 2002; Berger et al., 2004; Muthian et al., 2004) and other types of brain injury (Sugiura et al., 2000; Hansen et al., 2001a,b; Panikashvili et al., 2001).”
BackgroundCB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity
Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich, A., Azad, S. C., Cascio, M. G., Gutiérrez, S. O., van der Stelt, M., et al. (2003) · Science · doi:10.1126/science.1088208 · Cited by 1,208
Ligresti, A., De Petrocellis, L., & Di Marzo, V. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 469
Eljaschewitsch, E., Witting, A., Mawrin, C., Lee, T., Schmidt, P. M., Wolf, S., Hoertnagl, H., Raine, C. S., Schneider-Stock, R., Nitsch, R., et al. (2006) · Neuron · doi:10.1016/j.neuron.2005.11.027 · Cited by 445
SUGIURA, T., KISHIMOTO, S., OKA, S., & GOKOH, M. (2006) · Progress in Lipid Research · doi:10.1016/j.plipres.2006.03.003 · Cited by 352
Metadata
- Authors
- Hansen, H. H., Schmid, P. C., Bittigau, P., Lastres‐Becker, I., Berrendero, F., Manzanares, J., Ikonomidou, C., Schmid, H. H. O., Fernández‐Ruiz, J. J., & Hansen, H. S.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2001-09-15
- Volume
- 78
- Issue
- 6
- Pages
- 1415-1427
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1506884824
- Cited by
- 215
- References
- 7
- FWCI
- 10.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.